证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-176 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 HRS-2430 注射液为静脉全身麻醉药，已上市的同类产品有依托咪酯、咪达 唑仑、瑞马唑仑等。经查询，2024 年依托咪酯、咪达唑仑、瑞马唑仑全球销售 额合计约为 7.73 亿美元。截至目前，HRS-2430 注射液相关项目累计研发投入约 2,460 万元。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于 HRS-2430 注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-2430 注射液 剂 型：注射剂 申请事项：临床试验 受 理 号：CXHL2500810、CXHL2500811 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 4 日受理的 HRS-2430 注射液临 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-174 江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划第一次持有人会议决议 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、持有人会议召开情况 江苏恒瑞医药股份有限公司（以下简称"公司"）2025 年 A 股员工持股计 划第一次持有人会议于 2025 年 11 月 7 日以通讯会议的方式召开。会议由公司董 事会秘书刘笑含主持。本次会议应出席持有人 1,274 人，实际出席持有人 1,274 人，代表 2025 年 A 股员工持股计划有表决权的份额为 13,511,100 份，占 2025 年 A 股员工持股计划有表决权份额总数的 100%。 本次会议的召集、召开和表决程序符合相关法律法规、规范性文件及公司 2025 年 A 股员工持股计划的有关规定，会议合法有效。 二、持有人会议审议情况 经与会持有人逐项审议，通过以下议案： 根据《江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划》和《江苏恒 瑞医药股份有限公司 2025 年 A ...

一、药物的基本情况 药物名称：SHR-4610 注射液 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司上海盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-4610 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现 将相关情况公告如下： 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-175 三、风险提示 剂 型：注射剂 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 申请事项：临床试验 些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将 按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行信息披 露义务。 受 理 号：CXSL2500686 特 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-2430 injection, a new intravenous general anesthetic [1] Group 1: Product Development - HRS-2430 injection is designed for intravenous general anesthesia, competing with existing products such as etomidate, midazolam, and remimazolam [1] - The total global sales of etomidate, midazolam, and remimazolam are approximately $773 million in 2024 [1] - The cumulative R&D investment for the HRS-2430 injection project has reached approximately 24.6 million yuan [1]

Core Insights - GSK showcased its commitment to health management at the 8th China International Import Expo with the theme "Collaborate to Surpass, Create a Healthy Future" [1] - The company emphasizes a shift from disease-centered to health-centered pharmaceutical innovation, aligning with China's "Healthy China" initiative [1][2] - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for functional cure of chronic hepatitis B [1][2] Group 1: Product Innovations - GSK introduced a range of innovative pipeline products, including the first RSV vaccine approved globally and a long-acting drug for chronic hepatitis B [1] - The company also highlighted the first antibody-drug conjugate for multiple myeloma and a long-acting treatment for HIV [3] - GSK's new shingles vaccine is the first approved for adults with immunodeficiency due to known diseases or treatments [2] Group 2: Strategic Collaborations - GSK is collaborating with Hengrui Medicine to develop up to 12 innovative drugs across various therapeutic areas [3] - The company aims to deepen its local market presence with a strategy focused on speed, direction, and priority [3] - Over 80% of GSK's R&D projects in China are now integrated into global development, with approximately 18 new products expected to be approved in the next three years [3]

Core Viewpoint - The Medical Health R Index (480016) closed at 7535.01 points, down 0.39%, with a trading volume of 21.869 billion yuan and a turnover rate of 0.89% on November 7 [1] Group 1: Index Performance - The index had 26 stocks rising, with Xinhecheng leading at a 4.9% increase, while 23 stocks fell, with Zaiqing Pharmaceutical leading the decline at 4.35% [1] - The top ten constituent stocks of the Medical Health R Index are primarily in the pharmaceutical and medical sectors, with notable weights and market capitalizations [1] Group 2: Key Constituents - WuXi AppTec (sh603259) holds a weight of 13.66% with a market cap of 282.98 billion yuan, closing at 94.84 yuan, down 0.89% [1] - Hengrui Medicine (sh600276) has an 11.00% weight, a market cap of 408.72 billion yuan, and closed at 61.58 yuan, down 1.35% [1] - Mindray Medical (sz300760) has a weight of 7.57%, a market cap of 249.51 billion yuan, and closed at 205.79 yuan, down 0.27% [1] - Other notable constituents include United Imaging Healthcare (sh688271), Pianzai Shou (sh600436), and Xinhecheng (sz002001), which saw a 4.9% increase [1] Group 3: Capital Flow - The Medical Health R Index constituents experienced a net outflow of 240 million yuan from institutional investors and 119 million yuan from retail investors, while retail investors saw a net inflow of 359 million yuan [1] - Specific stocks like Huazhong Pharmaceutical (000999) and Yuyue Medical (002223) showed significant net inflows and outflows among different investor types [2]

【恒瑞医药：子公司收到SHR-4610注射液药物临床试验批准通知书】智通财经11月7日电，恒瑞医药 (600276.SH)公告称，子公司上海盛迪医药有限公司收到国家药监局核准签发关于SHR-4610注射液的 《药物临床试验批准通知书》，同意本品单药在晚期实体瘤中开展临床试验。SHR-4610注射液是公司 自主研发的创新型抗肿瘤药物，截至目前，相关项目累计研发投入约736万元。根据相关法律法规要 求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审评、审批通过后方可 生产上市。 转自：智通财经 ...

SHR-4610注射液是公司自主研发的创新型抗肿瘤药物，在临床前动物模型中展现出良好的抗肿瘤活 性，拟用于治疗晚期实体瘤。截至目前，SHR-4610注射液相关项目累计研发投入约736万元。 智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海盛迪医药有限公司收到国家 药品监督管理局(简称"国家药监局")核准签发关于SHR-4610注射液的《药物临床试验批准通知书》，将 于近期开展临床试验。 ...

Core Viewpoint - Heng Rui Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-2430 injection, a new intravenous general anesthetic [1] Company Summary - HRS-2430 injection is positioned as a competitor to existing products such as etomidate, midazolam, and remimazolam [1] - The total global sales of etomidate, midazolam, and remimazolam are approximately $773 million for the year 2024 [1] - The cumulative R&D investment for the HRS-2430 injection project has reached approximately 24.6 million yuan [1]

恒瑞医药公告，子公司上海盛迪医药有限公司收到国家药监局核准签发的SHR-4610注射液《药物临床 试验批准通知书》，将于近期开展临床试验。SHR-4610注射液是公司自主研发的创新型抗肿瘤药物， 拟用于治疗晚期实体瘤。截至目前，SHR-4610注射液相关项目累计研发投入约736万元。 ...